KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Intangibles (2016 - 2025)

Historic Intangibles for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $29.7 million.

  • Sarepta Therapeutics' Intangibles rose 766.78% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.7 million, marking a year-over-year increase of 766.78%. This contributed to the annual value of $26.9 million for FY2024, which is 922.69% down from last year.
  • Sarepta Therapeutics' Intangibles amounted to $29.7 million in Q3 2025, which was up 766.78% from $30.5 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Intangibles registered a high of $30.5 million during Q2 2025, and its lowest value of $7.2 million during Q1 2023.
  • Its 5-year average for Intangibles is $20.2 million, with a median of $19.5 million in 2023.
  • Its Intangibles has fluctuated over the past 5 years, first crashed by 6434.55% in 2022, then surged by 30186.14% in 2024.
  • Sarepta Therapeutics' Intangibles (Quarter) stood at $21.3 million in 2021, then plummeted by 64.35% to $7.6 million in 2022, then soared by 290.87% to $29.6 million in 2023, then fell by 9.23% to $26.9 million in 2024, then rose by 10.4% to $29.7 million in 2025.
  • Its last three reported values are $29.7 million in Q3 2025, $30.5 million for Q2 2025, and $26.2 million during Q1 2025.